Stock PAVM PAVMED INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News PAVmed Inc.

Equities

PAVM

US70387R4039

Delayed Nasdaq
Other stock markets
 12:06:53 2024-05-03 pm EDT 		5-day change 1st Jan Change
2.14 USD -4.46% Intraday chart for PAVmed Inc. +24.42% -48.06%
Mar. 27 Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024
Mar. 25 PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
PR
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
PR
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
PR
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
PR
PAVmed : Material Agreement - Form 8-K
PU
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
PR
Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
PR
PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
CI
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
PR
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
PR
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
PR
PAVmed : Failure to Satisfy Listing Rule - Form 8-K
PU
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
AQ
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
PR
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
PR
Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
AQ
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
PR
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PAVM Stock
  4. News PAVmed Inc.